Table 5. Cost per cardiomyopathy case averted (US$) using desired TPP vaccinea.
| |
SAE risk |
1 dose |
2 dose |
||||
|---|---|---|---|---|---|---|---|
| |
Vaccine protection duration |
||||||
| Compliance | 10 y | 20 y | Lifetime | 10 y | 20 y | Lifetime | |
|
100% |
0.1% |
-6,326 |
-5,475 |
-3,343 |
-6,407 |
-5,373 |
-3,301 |
| |
1% |
-5,567 |
-5,428 |
-3,196 |
-5,535 |
-5,011 |
-3,141 |
| |
3% |
-4,874 |
-5,027 |
-3,005 |
-143 |
-4,102 |
-2,681 |
| |
7% |
7,413 |
-3,638 |
-2,490 |
- b |
1,833 |
-1,188 |
| |
|
|
|
|
|
|
|
|
75% |
0.1% |
NA |
NA |
NA |
-6,692 |
-5,381 |
-3,283 |
| |
1% |
NA |
NA |
NA |
-4,660 |
-4,939 |
-3,109 |
| |
3% |
NA |
NA |
NA |
8,524 |
-3,684 |
-2,571 |
| |
7% |
NA |
NA |
NA |
- b |
6,472 |
-901 |
| |
|
|
|
|
|
|
|
|
50% |
0.1% |
NA |
NA |
NA |
-5,794 |
-5,345 |
-3,227 |
| |
1% |
NA |
NA |
NA |
-3,489 |
-4,748 |
-2,988 |
| |
3% |
NA |
NA |
NA |
- b |
-2,698 |
-2,294 |
| |
7% |
NA |
NA |
NA |
- b |
310,407 |
331 |
| |
|
|
|
|
|
|
|
|
25% |
0.1% |
NA |
NA |
NA |
-5,381 |
-4,880 |
-2,883 |
| |
1% |
NA |
NA |
NA |
2,291 |
-3,738 |
-2,607 |
| |
3% |
NA |
NA |
NA |
- b |
3,889 |
-1,064 |
| 7% | NA | NA | NA | - b | - b | 6,138 | |
NA, Not Applicable. aNegative costs, cost savings. bVaccination was more costly and caused more cardiomyopathy cases